Melatonin Treatment for Night-Eating Syndrome

Stopped early · Not applicable · Has a placebo group

Conditions studied: Night-eating Syndrome

In brief

This is an 8-week randomized, double-blind, placebo-controlled, parallel, fixed-dose pilot clinical trial to test the effectiveness of melatonin treatment versus placebo on symptoms of Night Eating Syndrome (NES). The investigators will also look at the effect of melatonin treatment on weight, metabolic parameters and sleep parameters in individuals with NES.

Key facts

Study ID

NCT02500017

Run by

Yale University

People needed

2

Starts

2015-09-24

Expected to finish

2017-04-25

Last updated by the study team

2018-01-23

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 18 - 65 years of age
• English speaking
• Meet DSM-V (Diagnostic and Statistical Manual - version 5) criteria for Night Eating Syndrome (NES)

You may not qualify if…

• Unable to provide informed consent
• Presence of alcohol/substance dependence
• Presence of other eating disorders such as Binge Eating Disorder, Anorexia Nervosa.
• Significant uncontrolled systemic illness (e.g. chronic renal failure, chronic liver disease, poorly controlled diabetes, poorly controlled congestive heart failure, chronic infectious disease, chronic autoimmune disease)
• Women who are pregnant or breastfeeding
• Allergy or hypersensitivity to melatonin

Where it is running

• Connecticut Mental Health Center — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.